Final results from a phase 3 trial with the investigational DCVax-L vaccine show that overall survival was increased both in patients with newly diagnosed glioblastoma as well as recurrent disease.
The study shows that ctDNA testing could help guide decisions about adjuvant chemotherapy. The study was published as a preprint and has not yet been peer reviewed.
Among patients with metastatic colon cancer with liver or lung lesions who received neoadjuvant therapy, survival was longer in comparison with patients who received adjuvant therapy, but only in nonacademic settings.